2.80Open2.80Pre Close0 Volume22 Open Interest5.00Strike Price0.00Turnover0.00%IV23.88%PremiumAug 16, 2024Expiry Date2.11Intrinsic Value100Multiplier25DDays to Expiry0.69Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.39Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Allogene Therapeutics Stock Discussion
NEWS
Allogene Therapeutics Q1 2024 GAAP EPS $(0.38) Beats $(0.41) Estimate, Sales $22.000K Down From $30.000K YoY
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 44.93 percent increase over losses of $(0.69) per share from the same period last year. The company reported $22.000 thousand in sales this quarter. This is a 26.67 percent decrease over sal...
NEWS
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
bottom of the channel, let's see if we can see this getting pumped to 2.50/2.56
@Alvinnnnnnn89 @AmyNic what do you guys think about this?
$Carvana(CVNA.US)$ $Allogene Therapeutics(ALLO.US)$ $Upstart(UPST.US)$ $Airsculpt Technologies(AIRS.US)$ $Marathon Digital(MARA.US)$
In reaction to earnings/guidance:
• $Aehr Test Systems(AEHR.US)$ +11.1% (also releases two new enhancements for its FOX-P family of wafer level test and burn-in systems)
• $Tilray Brands(TLRY.US)$ +5.1%
Other news:
• $Payoneer Global(PAYO.US)$ +8.1% (to join SaP SmallCap 600)
• $Atlas(ATCO.US)$ +6.8% (continues negotiations with Poseidon Acquisition; parties have made meaningful progress on potential transactio...
No comment yet